Filing Flows › Niagen Bioscience (NAGE) › Q3 2025
Niagen Bioscience (NAGE) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Niagen Bioscience (NAGE) reported revenue of $34.0M for the third quarter 2025 (Q3 2025), +33% from a year earlier and +9% from the quarter before. Operating margin was 12.5%, net earnings $4.6M (13.5% of revenue).
Niagen Bioscience, Q3 2025: revenue $34.0M (+33% year over year), operating margin 12.5%, net earnings $4.6M, operating cash flow $3.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34.0M | +9% | +33% |
| Gross profit | $21.9M | +8% | +35% |
| Operating profit | $4.2M | +33% | +164% |
| Net earnings | $4.6M | +27% | +144% |
| Operating cash flow | $3.7M | +195% | +6% |
What changed
Revenue was $34.0M in Q3 2025, up 33% year over year and up 9% from the previous quarter. Consumer Products segment was the largest line at 77% of revenue. Consumer Products segment added $7.9M year over year (up 44%), 94% of the total change. Analytical Reference Standards and Services segment declined 2%.
Gross margin was 64.5%, up 1.0 points from a year earlier. Operating profit was $4.2M, a 12.5% margin (up 6.2 points year over year). Of the extra revenue versus a year earlier, 31% reached operating profit, above the 6% margin then. Operating expenses grew 21% against revenue growth of 33%. The fastest-growing cost line was Research & development (+39%). Net earnings were $4.6M, up 144% year over year. The effective tax rate was 4.6%.
Operating cash flow was $3.7M (up 6% year over year), 81% of net earnings. Non-cash charges added back $195K of depreciation and amortization and $1.8M of share-based compensation. Working capital and other items used $2.8M.
Questions
What was Niagen Bioscience's revenue in the third quarter 2025?
Niagen Bioscience (NAGE) reported revenue of $34.0M for the third quarter 2025 (Q3 2025), +33% from a year earlier and +9% from the quarter before.
Was Niagen Bioscience profitable in the third quarter 2025?
Operating profit was $4.2M (12.5% of revenue) and net earnings $4.6M.
Source: Niagen Bioscience 10-Q on SEC EDGAR.